While we welcome the finalisation and adoption of this policy, we stress that it has not yet changed anything in the lives of people in South Africa who right now need medicines that remain unaffordable, and that it will not do so until key elements of the policy become law. As a matter of urgency, the dti must produce a thorough and far-reaching bill to amend the relevant Acts and parliament must prioritise the passing of this bill. Those aspects of the policy that can be implemented without legislative changes must be implemented right away. Whether the state can deliver the required legislative changes will be a key test of its commitment to the health of the people.
The harsh reality is that this law reform process in South Africa has already taken too long. It has taken too long for two of our comrades who have passed away in recent years, Tobeka Daki and Sue Johnson. At critical times in their illnesses, both Tobeka and Sue could not access the medicines they needed due to high prices. We will remember these comrades as we continue to advocate for more just and humane patent laws.
Comment on the content of the policy
As the Fix the Patent Laws coalition, we welcome the publication of the new policy and we are broadly in agreement with its content. The policy addresses most of the critical health-related policy and legislative changes that we have been campaigning for since 2011. We are disappointed though that certain critical sections of the policy are lacking in detail – in particular the sections on patentability criteria and on compulsory licensing.
That said, we welcome the policy’s framing in terms of the Constitution of South Africa and its acknowledgement of the importance of considering the public health impact of economic policy. We also welcome the policy’s acknowledgement that South Africa requires an intellectual property framework appropriate to its phase of development and that a patent maximalist approach is not in the best interest of our economy. In this regard, the policy implicitly rejects the incorrect view that trade-offs have to be made between the right to health and economic development.
We make the following specific comments:
1. We support the introduction of a substantive patent search and examination system for patents in South Africa – something we have been advocating for, for years. The policy recognises that the current depositary system, in which patent applications are granted if they meet procedural formalities (paperwork and filing fee), leads to an excessive number of poor quality patents being granted in comparison to other countries. Patent examination guidelines must now be published for public input and the examination of patent applications for pharmaceutical products must start as soon as possible.
2. We welcome the commitment to develop patentability criteria to “promote genuine innovation” – although we are disappointed that the policy does not go further to discourage specific evergreening practices. Ideally, the policy would have explicitly stated that South Africa will no longer grant patents for new uses, new forms, new formulations, combinations and other minor modifications of existing medicines. To improve the system, it is vital that South Africa develop rigorous patentability criteria and examination guidelines, following international best practices in countries of a similar developmental status, such as Argentina and India. By ensuring that only patents that meet rigorous criteria for novelty and inventiveness are granted, the government can curb excessive and secondary patenting, and ensure that only genuine innovation is rewarded. This will facilitate earlier introduction of more affordable generic medicines, ensuring that more people can access medicines earlier. Raising the bar for patentability is also necessary to incentivise R&D expenditure and efforts towards the development of meaningful health innovations that address unmet health needs, rather than perpetuating the pursuit of minor modifications and me-too versions of existing profitable products.
3. We welcome the long-term commitment to introducing pre- and post-grant patent opposition procedures that could help ensure that only those inventions that represent genuine innovation are granted patent protection. This has been another key ask of our campaign. However, we are concerned that the interim solution proposed by the policy—a third-party observation system and administrative law procedures—will not permit sufficient participation by third-parties. We instead encourage the rapid introduction of simplified opposition procedures, and greater transparency concerning patent applications to allow third parties, such as civil society groups and other pharmaceutical companies, to intervene.
4. We support the commitment to introduce a “more effective and efficient” system to obtain compulsory licenses for medicines – another key ask of our campaign in recent years. Compulsory licenses are a vital tool to ensure medicine access and must be available on a wide variety of grounds and in such a way that they can be granted quickly and effectively when needed for public health purposes. We urge government to withstand the industry pressure that will no doubt oppose this policy commitment, even though this commitment is entirely in line with World Trade Organisation rules.
We remain committed to engaging constructively with the DTI, the inter-ministerial committee on IP, and wider government to ensure rapid reforms to our patent laws to improve access to medicines in line with the state’s Constitutional obligations. We cannot wait another nine years for this policy to be turned into law. ________________________________________________________________________________________
For more information and to arrange interviews please contact:
Angela Makamure | Doctors Without Borders (MSF) | 079 872 2950 | firstname.lastname@example.org
Ntsiki Mpulo | SECTION27 | 082 782 7143 | email@example.com
Lotti Rutter | Treatment Action Campaign (TAC) | 072 225 9675 | firstname.lastname@example.org
The policy references the Fix the Patent Laws and cancer Alliance joint medicines report that outlines 24 specific cancer medicines that people have struggled to access as a result of patent barriers in South Africa: “Patent Barriers to Medicine Access in South Africa: A Case for Patent Law Reform”.
The report is available at http://www.fixthepatentlaws.org/wp-content/uploads/2016/09/MSF-FTPL-report-FINAL-VERSION.pdf
The Fix the Patent Laws Coalition, made up of 40 patient groups and civil society organisations representing most major diseases in South Africa was launched on 11 November 2011 (on the 10-year anniversary of the WTO Doha Declaration) to advocate for changes to South Africa’s Patent Laws.
Members include: Treatment Action Campaign (TAC), Doctors Without Borders (MSF), SECTION27, the South African Non-Communicable Diseases Alliance (SANCD Alliance), DiabetesSA, EpilepsySA, Marie Stopes South Africa, Stop Stock Outs Project (SSP), South African Depression and Anxiety Group (SADAG), Cape Mental Health (CMH), the South African Federation of Mental Health (SAFMH), Schizophrenia and Bipolar Disorders Alliance (SABDA),
as well as the following members of the Cancer Alliance and Advocates for Breast Cancer: Breast Course 4 Nurses, Breast Health Foundation, Cancer Association of South Africa (CANSA), Cancer Heroes, Can-Sir, CanSurvive, Care for Cancer Foundation, Childhood Cancer Foundation of South Africa (CHOC), Hospice Palliative Care Association (HPCA), Igazi Foundation, Look Good Feel Better, Love your Nuts, Lymphoedema Association of South Africa (LAOSA), Men's Foundation, National Council Against Smoking, National Oncology Nursing Association of SA, Pancreatic Cancer Network of SA (PanCan), People Living With Cancer (PLWC), Pink Trees for Pauline, Pink Phoenix Cancer Foundation, Pocket Cancer Support, Project Flamingo, Rainbows and Smiles, Reach for Recovery, South African Oncology Social Work Forum (SAOSWF), The Pink Parasol Project, The Sunflower Fund, Vrede Foundation and Wings of Hope.